Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 2/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6890839 | 0.98 | GNAI3 (0.40) | GNAI3GNAO1GNAI1 | |
| SCHEMBL6561478 | 0.98 | GNAI3 (0.40) | GNAI3GNAO1GNAI1 | |
| SCHEMBL7061616 | 0.98 | GNAI3 (0.40) | GNAI3GNAO1GNAI1 | |
| SCHEMBL8512227 | 0.94 | GNAI3 (0.32) | GNAI3GNAO1GNAI1 | |
| SCHEMBL8160090 | 0.88 | GNAO1 (0.43) | GNAI3GNAO1GNAI1 | |
| SCHEMBL11595655 | 0.80 | — | — | |
| SCHEMBL11597294 | 0.78 | — | — | |
| SCHEMBL3513744 | 0.78 | — | — | |
| SCHEMBL11594967 | 0.78 | — | — | |
| SCHEMBL727413 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115121233-A | Modified silica gel mixed mode chromatographic stationary phase, preparation method and application | 武汉工程大学 | 2022-09-30 | — | — | CN | claimed |
| EP-0925283-B1 | NOVEL POLYMERIZABLE ACYL IMIDAZOLIDINONE MONOMERS | CYTEC TECH CORP (US) | 2003-11-12 | — | — | EP | claimed |
| EP-0925283-A1 | NOVEL POLYMERIZABLE ACYL IMIDAZOLIDINONE MONOMERS | Cytec Technology Corp. (US) | 1999-06-30 | — | — | EP | claimed |
| WO-1997049686-A1 | NOVEL POLYMERIZABLE ACYL IMIDAZOLIDINONE MONOMERS | CYTEC TECHNOLOGY CORP. (US) | 1997-12-31 | — | — | WO | claimed |
| JP-7082268-A | — | — | None | — | — | JP | disclosed |
| CN-115121233-A | Modified silica gel mixed mode chromatographic stationary phase, preparation method and application | 武汉工程大学 | 2022-09-30 | — | — | CN | disclosed |
| CN-115121233-A | Modified silica gel mixed mode chromatographic stationary phase, preparation method and application | 武汉工程大学 | 2022-09-30 | — | — | CN | disclosed |
| US-20100317649-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-7790707-B2 | S1P receptor modulating compounds and use thereof | EPIX PHARMACEUTICALS INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2010524-A2 | S1P RECEPTOR MODULATING COMPOUNDS | Epix Delaware, Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080015177-A1 | S1P receptor modulating compounds and use thereof | AMGEN INC. | 2008-01-17 | — | — | US | disclosed |
| WO-2007109330-A3 | S1P RECEPTOR MODULATING COMPOUNDS | EPIX DELAWARE INC (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-1999010312-A1 | N-ALKANOYLPHENYLALANINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-04 | — | — | WO | disclosed |
| WO-1997049686-A1 | NOVEL POLYMERIZABLE ACYL IMIDAZOLIDINONE MONOMERS | CYTEC TECHNOLOGY CORP. (US) | 1997-12-31 | — | — | WO | disclosed |
| WO-1997049686-A1 | NOVEL POLYMERIZABLE ACYL IMIDAZOLIDINONE MONOMERS | CYTEC TECHNOLOGY CORP. (US) | 1997-12-31 | — | — | WO | disclosed |
| US-5482867-A | Spatially-addressable immobilization of anti-ligands on surfaces | AFFYMAX TECHNOLOGIES N.V. (NL) | 1996-01-09 | — | — | US | disclosed |
| US-5451683-A | Spatially-addressable immobilization of anti-ligands on surfaces | AFFYMAX TECHNOLOGIES N.V. | 1995-09-19 | — | — | US | disclosed |
| JP-H0782268-A | PRODUCTION OF BENZOTHIADIAZOLE DERIVATIVE | PERMACHEM ASIA LTD | 1995-03-28 | — | — | JP | disclosed |
| US-4210760-A | Processes for dehydrogenation of arylimidazolidones | AMERICAN CYANAMID COMPANY (US) | 1980-07-01 | — | — | US | disclosed |
| US-4210760-A | Processes for dehydrogenation of arylimidazolidones | AMERICAN CYANAMID COMPANY (US) | 1980-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015177-A1 | S1P receptor modulating compounds and use thereof | S1PR1, S1PR2, S1PR5 | GNAI3 156/4885GNAO1 420/4885GNAI1 155/4885 |
| US-20100317649-A1 | S1P Receptor Modulating Compounds and Use Thereof | S1PR1, S1PR2, S1PR5 | GNAI3 156/4885GNAO1 420/4885GNAI1 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.